PDF(Pubmed)
Abstract：
Lung cancer is the leading cause of cancer-related death worldwide, especially non-small cell lung cancer. Early diagnosis and better treatment choices have already provided a more promising prognosis for cancer patients. In targeted therapy, antagonists target specific genes supporting cancer growth, proliferation and metastasis. With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents must be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. Drug-related nephrotoxicity has attracted attention when initiating cancer therapy. Our review aims to summarize the adverse renal effects caused by targeted therapy during lung cancer treatment, mainly focusing on EGFR and ALK tyrosine kinase inhibitors. Also, we discuss the possible mechanism of the side effect and provide managements to help improve the renal function in clinical practice.
摘要：
肺癌是全球癌症相关死亡的主要原因，尤其是非小细胞肺癌。早期诊断和更好的治疗选择已经为癌症患者提供了更有希望的预后。在靶向治疗中,拮抗剂靶向支持癌症生长的特定基因，增殖和转移。随着靶向治疗在常规癌症治疗中的应用，与这些药物相关的一系列毒性必须得到良好的认可和管理，特别是因为这些毒性与常规细胞毒性剂不同。在开始癌症治疗时，药物相关的肾毒性引起了人们的注意。我们的综述旨在总结肺癌治疗过程中靶向治疗引起的不良肾脏反应。主要集中于EGFR和ALK酪氨酸激酶抑制剂。此外，我们讨论了副作用的可能机制，并提供了治疗方法，以帮助临床改善肾功能。
